JPMorgan Reinstates Teva Pharma (TEVA) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
Teva Pharma (TEVA) Tops Q2 EPS by 12c; Boosts FY15 EPS Outlook
July 30, 2015 7:06 AM EDTTeva Pharma (NYSE: TEVA) reported Q2 EPS of $1.43, $0.12 better than the analyst estimate of $1.31. Revenue for the quarter came in at $4.97 billion versus the consensus estimate of $4.9 billion.
Teva Pharma sees FY2015 EPS of $5.15-$5.40, versus prior guidance of $5.05-$5.35 and the consensus of... More
